Heat Biologics Takes Heat For Failed Bladder Cancer Trial

Shutterstock photo

(RTTNews.com) - Shares of Heat Biologics Inc. ( HTBX ) tumbled nearly 57% in extended trading on Wednesday, following disappointing results from its phase II study of bladder cancer cell vaccine HS-410 in the treatment of non-muscle invasive bladder cancer.

The trial evaluated HS-410 in combination with standard of care, Bacillus Calmette-Guérin (BCG), and as a monotherapy against placebo, with one-year disease free survival as the primary endpoint.

According to the trial results, although there were encouraging signs of anti-tumor activity with HS-410, there was no statistically significant difference in the primary endpoint between the vaccine and placebo arms of the trial.

Shares of Heat Biologics had gained over 134% in the last 7 trading days in the run-up to the announcement of the trial results. But with HS-410 failing the mid-stage study, Heat Biologics' rally has come to an end.

HTBX closed Wednesday's trading at $2.87, down 3.69%. In after-hours, the stock plummeted 56.10% to $1.26.

For comments and feedback: contact editorial@rttnews.com


This article appears in: News Headlines
Referenced Symbols: HTBX

More from RTT News


See headlines for HTBX

Follow on: